• Completed

Phase 2: Antitumor Activity of Thalidomide in Refractory Multiple Myeloma - NEJM 1999

Time Frame: December 1997 and June 1998

Phase 2: Antitumor Activity of Thalidomide in Refractory Multiple Myeloma - NEJM 1999

thalidomide dr barlogie myeloma

Antitumor Activity of Thalidomide in Refractory Multiple Myeloma

Seema Singhal, M.D., Jayesh Mehta, M.D., Raman Desikan, M.D., Dan Ayers, M.S., Paula Roberson, Ph.D., Paul Eddlemon, B.S., Nikhil Munshi, M.D., Elias Anaissie, M.D., Carla Wilson, M.D., Ph.D., Madhav Dhodapkar, M.D., Jerome Zeldis, M.D., David Siegel, M.D., Ph.D., John Crowley, Ph.D., and Bart Barlogie, M.D., Ph.D.

NEJM - November 18, 1999


Phase 2: Antitumor Activity of Thalidomide in Refractory Multiple Myeloma - NEJM 1999

Click here for details


Archives NY Times - Beth Wolmer / Ira Wolmer, M.D.

Thalidomide Found to Slow a Bone Cancer

Click here for details









Posts Archive